FDA's second biosimilar approval, Celltrion Inc.'s Inflectra (infliximab-dyyb), is a practical application of the agency's draft naming and labeling policies developed after the first biosimilar was approved. The result is description of a product that is more clearly different than, but also more closely tied to, its brand reference.
Inflectra, a biosimilar of Janssen Biotech Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?